Compare Inovio Pharmaceuticals Inc (INO) vs Toro Company (The) Common Stock (TTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Toro Company (The) Common Stock — how do they compare? Inovio Pharmaceuticals Inc trades at $1.18 (market cap $101.95M), while Toro Company (The) Common Stock trades at $98.27 (market cap $9.30B). The key difference: Toro Company (The) Common Stock is far larger — about 91.2× Inovio Pharmaceuticals Inc's market cap, and Toro Company (The) Common Stock pays a 1.59% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Toro Company (The) Common Stock for 0 Days on average.
| INO | TTC | |
|---|---|---|
Market Cap | $101.95M | $9.30B |
Volume | 2,985,847 | 420,909 |
Sector | Health | Industrials |
52-Week High | $2.60 | $101.76 |
52-Week Low | $0.66 | $67.99 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $73.28M | $10.20B |
Dividend Yield | — | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $0.9982, down 9.67% in the last session, with a bearish technical signal and negative financial metrics including a net income margin of -130,000%. The company shows consistent quarterly earnings beats but faces significant cash burn, with operating cash flow negative at -$88.63M in 2025. Key near-term catalyst is the FDA decision on INO-3107 expected by October 30, 2026.
INO presents high-risk speculative opportunity with analyst consensus price target of $2.75 representing 175% upside potential. The investment case hinges on successful FDA approval and commercialization of INO-3107, but carries substantial risk from persistent losses, negative cash flow, and dependence on financing activities to sustain operations.
Toro Company (TTC) trades at $97.88, up 1.27% with strong technical momentum above its 50-day moving average. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.33 beating expectations of $1.31, and raised full-year guidance. Revenue growth of 8.4% in Q3 2026 to $1.23 billion reflects robust demand across professional and residential segments, supported by infrastructure and automation initiatives under new CEO leadership.
Toro presents a balanced investment case with 36% analyst buy ratings and $117.50 price target suggesting 20% upside. However, execution risks from inflation, tariffs, and competitive pressures warrant caution. The stock's premium valuation (P/E 26.17) requires sustained earnings growth, making Q3 2026 results critical for validating current momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Toro Company (The) Common Stock
The Toro Company designs, manufactures, and markets equipment for turf maintenance, snow and ice management, landscaping, construction, and irrigation. Its products serve golf courses, sports fields, and residential and commercial properties in more than 125 countries.
Read more on TTC →
